NTRB
Nutriband·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NTRB
Nutriband Inc.
A developer of transdermal pharmaceutical products for currently injected compounds
121 South Orange Ave.
Suite 1500
Orlando
FL32801
--
Nutriband Inc., a Nevada corporation, was founded on January 4, 2016. They are primarily engaged in the development of a transdermal drug portfolio. Their primary product is their Abuse Deterrence Fentanyl Transdermal System, and they are developing a slow-release fentanyl transdermal product for clinicians and patients for the treatment of chronic pain requiring round-the-clock opioid therapy, combined with properties designed to help combat the opioid crisis by discouraging abuse and misuse of fentanyl patches.
Company Financials
EPS
NTRB has released its 2026 Q2 earnings. EPS was reported at -2.12, versus the expected -0.17, missing expectations. The chart below visualizes how NTRB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NTRB has released its 2026 Q2 earnings report, with revenue of 622.45K, reflecting a YoY change of 40.56%, and net profit of -2.00M, showing a YoY change of -17.29%. The Sankey diagram below clearly presents NTRB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
